<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Anesthesiol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Anesthesiol</journal-id><journal-title-group><journal-title>BMC Anesthesiology</journal-title></journal-title-group><issn pub-type="epub">1471-2253</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27449404</article-id><article-id pub-id-type="pmc">4957928</article-id><article-id pub-id-type="publisher-id">210</article-id><article-id pub-id-type="doi">10.1186/s12871-016-0210-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Ramosetron versus ondansetron for postoperative nausea and vomiting in strabismus surgery patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Joo</surname><given-names>Jin</given-names></name><address><email>jiyo1004@catholic.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Shinhye</given-names></name><address><email>vaccine@catholic.ac.kr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Hue Jung</given-names></name><address><email>huejung@catholic.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shin</surname><given-names>Sun Young</given-names></name><address><phone>82-2-2258-6202</phone><email>eyeshin@catholic.ac.kr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Anesthesiology and Pain Medicine, Seoul St. Mary&#x02019;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea </aff><aff id="Aff2"><label>2</label>Department of Ophthalmology, Seoul St. Mary&#x02019;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><elocation-id>41</elocation-id><history><date date-type="received"><day>26</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Joo et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Postoperative nausea and vomiting (PONV) is one of the most common adverse outcomes after strabismus surgery. The primary outcome of this prospective, randomized, double-blind study was to compare the incidences of nausea or vomiting, and patient satisfaction of ondansetron and ramosetron after strabismus surgery under general anesthesia. The secondary outcome was to investigate whether the number of involved extraocular muscles (EOMs) in strabismus surgery was related to PONV.</p></sec><sec><title>Methods</title><p id="Par2">One hundred and five patients (aged 18&#x02013;60 years) undergoing strabismus surgery were allocated randomly to one of the three groups: placebo, ondansetron, or ramosetron. Patients received 2&#x000a0;ml placebo, 4&#x000a0;mg ondansetron, or 0.3&#x000a0;mg ramosetron at the end of surgery. Each of the three groups was subdivided into two subgroups according to the number of EOMs involved in the surgery: subgroup S, single-muscle correction; subgroup M, multiple-muscle correction. The incidences of nausea or vomiting, and patient satisfaction at 2, 24 and 48&#x000a0;h after surgery were analyzed as primary outcome. With regard to subgroups S and M in the placebo, ondansetron and ramosetron groups, incidences of nausea or vomiting, and patient satisfaction at 2, 24 and 48&#x000a0;h after surgery were analyzed as seconadary outcome.</p></sec><sec><title>Results</title><p id="Par3">The incidence of nausea was significantly lower in the ramosetron group at 2&#x000a0;h (9.4&#x000a0;%) than in the placebo (45.2&#x000a0;%) and ondansetron (34.7&#x000a0;%) groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). The incidence of nausea was also significantly lower in the ramosetron group at 24&#x000a0;h than in the other groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Patients in the ramosetron group were more satisfied at 2&#x000a0;h (8.11&#x02009;&#x000b1;&#x02009;0.98) and 24&#x000a0;h (8.50&#x02009;&#x000b1;&#x02009;0.67) after surgery than those in the other groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). With regard to subgroups S and M in the placebo, ondansetron and ramosetron groups, there were no significant differences in either the incidence of nausea or patient satisfaction.</p></sec><sec><title>Conclusion</title><p id="Par4">Ramosetron has superior antiemetic activity to ondansetron in adult strabismus surgery patients. The number of EOMs involved in strabismus surgery was not related to the incidence of PONV.</p></sec><sec><title>Trial registration</title><p id="Par5">Clinical Research Information Service (CRiS) Identifier: <ext-link ext-link-type="uri" xlink:href="https://cris.nih.go.kr">KCT0000688</ext-link>. Date of registration: 27 February 2013.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Postoperative nausea</kwd><kwd>Strabismus surgery</kwd><kwd>Ramosetron</kwd><kwd>Ondansetron</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par6">Postoperative nausea and vomiting (PONV) is one of the most common adverse outcomes after strabismus surgery under general anesthesia, with an incidence of 37&#x02013;80&#x000a0;% [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. PONV may delay discharge from hospital or cause unexpected hospitalization in severe cases not only that it lowers patient&#x02019;s satisfaction after surgery.</p><p id="Par7">There are several known methods for PONV prophylaxis. Serotonin (5-HT<sub>3</sub>) receptor antagonists are recommended as the first-line regimen for PONV prophylaxis [<xref ref-type="bibr" rid="CR5">5</xref>]. Ondansetron, the first 5-HT<sub>3</sub> receptor antagonist used clinically for the prevention and management of PONV, acts less selectively on the 5-HT<sub>3</sub> receptor than other 5-HT<sub>3</sub> antagonists. Systemic review has revealed that the prophylactic effect of ondansetron on nausea is questionable although it has fine prophylactic effect on vomiting [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Ramosetron, a newer 5-HT<sub>3</sub> antagonist, has higher affinity to the 5-HT<sub>3</sub> receptor and longer duration of action, and has a similar or greater prophylactic effect on PONV compared with older 5-HT<sub>3</sub>&#x02013;receptor antagonists such as granisetron and ondansetron [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par8">Traction of extraocular muscles (EOMs) is one of the factors that trigger PONV after strabismus surgery, which induces the oculoemetic reflex [<xref ref-type="bibr" rid="CR11">11</xref>]. We hypothesized that more PONV would occur as the number of EOMs involved in strabismus surgery increases, causing more muscle traction. To our knowledge, no previous reports of the relationship between the numbers of involved EOMs and PONV have been published.</p><p id="Par9">Thus, we primarily designed this prospective, randomized, double-blind study to compare the incidences of nausea or vomiting, and patient satisfaction of ondansetron and ramosetron after strabismus surgery under general anesthesia in patients aged&#x02009;&#x0003e;&#x02009;18&#x000a0;years. The secondary outcome was to investigate whether the number of involved extraocular muscles (EOMs) in strabismus surgery was related to PONV.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par10">One hundred twenty patients aged between 18 and 60&#x000a0;years, ASA physical status I and II, and scheduled for strabismus surgery under general anesthesia were enrolled from April 2011 to April 2012 in this prospective, randomized, double-blind clinical study. Patients who took any analgesics, steroids or antiemetics 24&#x000a0;h before surgery, or who had gastrointestinal diseases were excluded.</p><p id="Par11">Recruited patients were allocated randomly to receive one of the following three drugs at the end of surgery: intravenous (IV) placebo (normal saline), ondansetron (4&#x000a0;mg), or ramosetron (0.3&#x000a0;mg) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. A computerized randomization list was generated, and identical syringes (2&#x000a0;ml total) containing each drug were prepared by personnel not involved in the study, according to the list.</p></sec><sec id="Sec4"><title>Study protocol</title><p id="Par12">All patients were allowed to take solid food up to 8&#x000a0;h before surgery and water up to 2&#x000a0;h before surgery. No premedication was administered to the patients. Electrocardiogram, non-invasive blood pressure, heart rate, and pulse oximetry were measured continuously at 5-min intervals, starting from the time of arrival in the operating room. General anesthesia was induced with 2&#x000a0;mg/kg propofol and 0.6&#x000a0;mg/kg rocuronium. After tracheal intubation, anesthesia was maintained with 1.5&#x02013;2&#x000a0;vol.% sevoflurane, medical air in oxygen [fraction of inspired O<sub>2</sub> (FiO<sub>2</sub>)&#x02009;=&#x02009;0.5], and continuously infused IV remifentanil 0.05&#x02013;0.1&#x000a0;&#x003bc;g/kg/min, keeping end-tidal CO<sub>2</sub> between 35 and 40&#x000a0;mmHg throughout the surgery. Ringer&#x02019;s lactate solution was administered at 6&#x02013;8&#x000a0;ml/kg/h during surgery. The nasopharyngeal temperature was monitored and maintained at 36&#x02009;&#x000b1;&#x02009;1&#x000a0;&#x000b0;C throughout surgery using a warming pad. The types of strabismus surgery included were unilateral rectus muscle recession, unilateral rectus muscle resection, bilateral rectus muscle recession, and bilateral rectus muscle resection. At the end of the surgical procedure, sevoflurane and remifentanil administration were discontinued. IV 0.2&#x000a0;mg/kg pyridostigmine and 0.008&#x000a0;mg/kg glycopyrrolate were administered for reversal of muscle relaxation, along with the assigned study drug. The trachea was extubated when spontaneous respiration of the patient was adequate.</p><p id="Par13">After the operation, the patients were transferred to the postanesthesia care unit. Every episode of nausea or vomiting was recorded during the first 2&#x000a0;h after surgery, and the presence of nausea at 2&#x000a0;h after surgery was asked by a member of the nursing staff who was blinded to the study drug used. She also filled out the data table including the followings: presence of nausea and vomiting, use of rescue antiemetics, patient&#x02019;s satisfaction, degree of pain, use of rescue analgesics, and presence of adverse effects of the study drugs, such as headache, dizziness, or drowsiness. The patients were asked to grade their satisfaction from 0 to 10 (VRS, verbal rating scale), where 0 represents total dissatisfaction and 10 represents the most satisfactory subjective answer. The degree of pain was recorded using a visual rating scale (VRS) with options from 0 (not painful at all) to 10 (extremely painful).</p><p id="Par14">If VRS score was&#x02009;&#x0003e;&#x02009;3 for&#x02009;&#x0003e;&#x02009;5&#x000a0;min, 30&#x000a0;mg IV ketorolac was administered for rescue analgesia. If patients complained of severe pain (VRS&#x02009;&#x0003e;&#x02009;7), 1&#x000a0;&#x003bc;g/kg fentanyl was administered. When patients complained of nausea or vomitted, 10-mg IV metoclopramide was administered as a rescue antiemetic.</p><p id="Par15">Patients were discharged from the hospital unless they showed severe complications of anesthesia, such as fever or desaturation due to laryngospasm or atelectasis. At 24 and 48&#x000a0;h after surgery, a resident of the Department of Ophthalmology who was also blinded to the study drug used completed the data table via telephone call.</p><p id="Par16">After completion of data collection, patients were subdivided into two groups according to the number of EOMs involved in the surgery: subgroup S, single-muscle correction; and subgroup M, multiple-muscle correction.</p></sec><sec id="Sec5"><title>Statistical analyses</title><p id="Par17">To estimate the required sample size, a power analysis was used. We aimed for an 80&#x000a0;% probability (&#x003b2;&#x02009;=&#x02009;0.2) of detecting a 50&#x000a0;% difference with a significance level (&#x003b1;) of 0.05, based on the incidence of PONV being 50&#x000a0;% in the placebo group and 20&#x000a0;% in the ramosetron group from our pilot study; thus 25 patients per group were required. To account for exclusion of some patients, we enrolled 35 patients in each group. Statistical analysis was performed using the SPSS, version 18.0 (SPSS, Chicago, IL, USA). Demographic data were analyzed by Student&#x02019;s <italic>t</italic>-test. Differences in the incidence of nausea and vomiting, and use of rescue antiemetics were analyzed by <italic>&#x003c7;</italic>
<sup>2</sup> test. Patient&#x02019;s satisfaction and pain were compared using one-way ANOVA with <italic>post hoc</italic> Bonferroni correction for multiple comparisons; data are presented as mean&#x02009;&#x000b1;&#x02009;SD. Intention-to-treat (ITT) analysis was conducted using last-observation-carried-forward (LOCF) imputation for missing values. A value of <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered to indicate statistical significance.</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par18">Among 120 patients recruited, 12 patients were excluded because they did not meet inclusion criteria; they showed ASA physical status &#x0003e;2. Another three patients were excluded because they did not agree to participate. Hence, 105 were randomly allocated to three groups. Among 16 follow-up loss patients, three patients and 13 patients did not respond to 24&#x000a0;h and 48&#x000a0;h telephone call, respectively (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Since persistent prophylactic effect on PONV was in concern, all the follow-up loss patients were excluded. There were no significant differences in patients&#x02019; characteristics, Apfel&#x02019;s four risk factors for PONV (female gender, nonsmoking, prior history of motion sickness or PONV, and the use of intraoperative opioids) [<xref ref-type="bibr" rid="CR14">14</xref>], and the duration of surgery and anesthesia among the groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram of the study</p></caption><graphic xlink:href="12871_2016_210_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patients&#x02019; characteristics and clinical data</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>Placebo</th><th>Ondansetron</th><th>Ramosetron</th></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;31)</th><th>(<italic>n</italic>&#x02009;=&#x02009;26)</th><th>(<italic>n</italic>&#x02009;=&#x02009;32)</th></tr></thead><tbody><tr><td>Age, years</td><td>34.10&#x02009;&#x000b1;&#x02009;15.14</td><td>35.69&#x02009;&#x000b1;&#x02009;17.13</td><td>34.13&#x02009;&#x000b1;&#x02009;13.66</td></tr><tr><td>Weight, kg</td><td>61.38&#x02009;&#x000b1;&#x02009;9.50</td><td>65.32&#x02009;&#x000b1;&#x02009;10.63</td><td>59.64&#x02009;&#x000b1;&#x02009;10.39</td></tr><tr><td>Height, cm</td><td>163.82&#x02009;&#x000b1;&#x02009;10.79</td><td>167.70&#x02009;&#x000b1;&#x02009;9.63</td><td>165.49&#x02009;&#x000b1;&#x02009;10.33</td></tr><tr><td>Sex, M/F</td><td>14/17</td><td>14/12</td><td>13/19</td></tr><tr><td>PONV Hx., n (%)</td><td>2 (6.45)</td><td>2 (7.69)</td><td>2 (6.25)</td></tr><tr><td>Motion sickness, n (%)</td><td>12 (38.71)</td><td>10 (38.46)</td><td>13 (40.63)</td></tr><tr><td>Non-smoker, n (%)</td><td>20 (64.52)</td><td>17 (65.38)</td><td>21 (65.63)</td></tr><tr><td>Duration of surgery, min</td><td>23.90&#x02009;&#x000b1;&#x02009;3.82</td><td>24.32&#x02009;&#x000b1;&#x02009;3.72</td><td>24.05&#x02009;&#x000b1;&#x02009;2.36</td></tr><tr><td>Duration of anesthesia, min</td><td>35.24&#x02009;&#x000b1;&#x02009;7.92</td><td>35.95&#x02009;&#x000b1;&#x02009;4.26</td><td>36.64&#x02009;&#x000b1;&#x02009;4.97</td></tr></tbody></table><table-wrap-foot><p>Data are means&#x02009;&#x000b1;&#x02009;SD or numbers. <italic>F</italic> female, <italic>M</italic> male</p></table-wrap-foot></table-wrap>
</p><p id="Par19">The total incidences of nausea were 29.2&#x000a0;% (26/89) at 2&#x000a0;h, 14.6&#x000a0;% (13/89) at 24&#x000a0;h, and 1.1&#x000a0;% (1/89) at 48&#x000a0;h after surgery. The incidence of nausea was significantly lower in the ramosetron group at 2&#x000a0;h (9.4&#x000a0;%) than in the placebo (45.2&#x000a0;%) and ondansetron (34.6&#x000a0;%) groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). The incidence of nausea was also significantly lower in the ramosetron group at 24&#x000a0;h (3.1&#x000a0;%) than in the placebo (22.6&#x000a0;%) and ondansetron (19.2&#x000a0;%) groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). There was no significant difference in the incidence of nausea at 48&#x000a0;h after surgery. The ondansetron group, comparing with the placebo group, showed significantly lower incidence of nausea only at 2&#x000a0;h after surgery (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). The ITT analysis using LOCF imputation for missing values revealed similar results (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). No patient showed vomiting after surgery. The incidence of rescue antiemetic use was identical significantly lower in the ramosetron group than in the other groups. No patients required fentanyl as rescue analgesics (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Incidence of nausea. Per- protocol analysis (<bold>a</bold>) and intention-to-treat analysis (<bold>b</bold>). <italic>*P</italic>&#x02009;&#x0003c;&#x02009;0.05 versus placebo group, &#x02020;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 versus ondansetron group</p></caption><graphic xlink:href="12871_2016_210_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Use of rescue analgesics and antiemetics in postanestheia unit</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>Placebo</th><th>Ondansetron</th><th>Ramosetron</th></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;31)</th><th>(<italic>n</italic>&#x02009;=&#x02009;26)</th><th>(<italic>n</italic>&#x02009;=&#x02009;32)</th></tr></thead><tbody><tr><td>Use of rescue analgesics, n (%)</td><td>17 (54.84)</td><td>14 (53.85)</td><td>18 (56.25)</td></tr><tr><td>Use of rescue antiemetics, n (%)</td><td>14 (45.2)</td><td>9 (34.6)*</td><td>3 (9.4)*&#x02020;</td></tr></tbody></table><table-wrap-foot><p>
<italic>*P</italic>&#x02009;&#x0003c;&#x02009;0.05 versus placebo group, &#x02020;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 versus ondansetron group</p></table-wrap-foot></table-wrap>
</p><p id="Par20">Patients in the ramosetron group were more satisfied at 2&#x000a0;h (8.11&#x02009;&#x000b1;&#x02009;0.98) and 24&#x000a0;h (8.50&#x02009;&#x000b1;&#x02009;0.67) after surgery than those in the placebo (6.84&#x02009;&#x000b1;&#x02009;1.34, 7.25&#x02009;&#x000b1;&#x02009;1.29, respectively at 2&#x000a0;h and 24&#x000a0;h) and those in the ondansetron (7.28&#x02009;&#x000b1;&#x02009;1.83, 7.27&#x02009;&#x000b1;&#x02009;1.59, respectively at 2&#x000a0;h and 24&#x000a0;h) groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). There was no significant difference in satisfaction in the patients at 48&#x000a0;h after surgery among any of the groups. The placebo and ondansetron groups showed no significant difference in patient satisfaction at all times after surgery (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). There were no significant differences in the degree of pain and incidence of adverse effects of antiemetics among the groups (Tables&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and <xref rid="Tab4" ref-type="table">4</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Patient satisfaction. VRS, verbal rating scale. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 versus placebo group, &#x02020;<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 versus ondansetron group</p></caption><graphic xlink:href="12871_2016_210_Fig3_HTML" id="MO3"/></fig>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Degree of pain</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>Placebo</th><th>Ondansetron</th><th>Ramosetron</th><th rowspan="2">
<italic>P</italic> value</th></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;31)</th><th>(<italic>n</italic>&#x02009;=&#x02009;26)</th><th>(<italic>n</italic>&#x02009;=&#x02009;32)</th></tr></thead><tbody><tr><td colspan="5">VAS</td></tr><tr><td>&#x02003;2&#x000a0;h</td><td>3.81&#x02009;&#x000b1;&#x02009;1.87</td><td>3.35&#x02009;&#x000b1;&#x02009;1.52</td><td>3.43&#x02009;&#x000b1;&#x02009;1.74</td><td>ns</td></tr><tr><td>&#x02003;24&#x000a0;h</td><td>2.58&#x02009;&#x000b1;&#x02009;1.52</td><td>2.08&#x02009;&#x000b1;&#x02009;1.41</td><td>2.19&#x02009;&#x000b1;&#x02009;1.31</td><td>ns</td></tr><tr><td>&#x02003;48&#x000a0;h</td><td>1.32&#x02009;&#x000b1;&#x02009;1.40</td><td>1.58&#x02009;&#x000b1;&#x02009;2.02</td><td>1.44&#x02009;&#x000b1;&#x02009;1.19</td><td>ns</td></tr></tbody></table><table-wrap-foot><p>Data are means&#x02009;&#x000b1;&#x02009;SD. <italic>VAS</italic> visual analogue scale</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Adverse effects of antiemetics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>Placebo</th><th>Ondansetron</th><th>Ramosetron</th><th rowspan="2">
<italic>P</italic> value</th></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;31)</th><th>(<italic>n</italic>&#x02009;=&#x02009;26)</th><th>(<italic>n</italic>&#x02009;=&#x02009;32)</th></tr></thead><tbody><tr><td colspan="5">Headache</td></tr><tr><td>&#x02003;2&#x000a0;h</td><td>7 (22.6)</td><td>3 (11.5)</td><td>9 (28.1)</td><td>ns</td></tr><tr><td>&#x02003;24&#x000a0;h</td><td>7 (22.6)</td><td>2 (7.7)</td><td>3 (9.4)</td><td>ns</td></tr><tr><td>&#x02003;48&#x000a0;h</td><td>1 (3.2)</td><td>0 (0)</td><td>0 (0)</td><td>ns</td></tr><tr><td colspan="5">Dizziness</td></tr><tr><td>&#x02003;2&#x000a0;h</td><td>7 (22.6)</td><td>4 (15.4)</td><td>4 (12.5)</td><td>ns</td></tr><tr><td>&#x02003;24&#x000a0;h</td><td>1 (3.2)</td><td>2 (7.7)</td><td>2 (6.3)</td><td>ns</td></tr><tr><td>&#x02003;48&#x000a0;h</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>ns</td></tr><tr><td colspan="5">Drowsiness</td></tr><tr><td>&#x02003;2&#x000a0;h</td><td>3 (9.7)</td><td>4 (15.4)</td><td>2 (6.3)</td><td>ns</td></tr><tr><td>&#x02003;24&#x000a0;h</td><td>0 (0)</td><td>0 (0)</td><td>1 (3.1)</td><td>ns</td></tr><tr><td>&#x02003;48&#x000a0;h</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>ns</td></tr></tbody></table><table-wrap-foot><p>Data are numbers (percentages)</p></table-wrap-foot></table-wrap>
</p><p id="Par21">With regard to subgroups S and M in the placebo, ondansetron and ramosetron groups, there were no significant differences in either the incidence of nausea or patient satisfaction (Figs.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> and <xref rid="Fig5" ref-type="fig">5</xref>). The ITT analysis also showed similar results.<fig id="Fig4"><label>Fig. 4</label><caption><p>Incidence of nausea regarding the number of extraocular muscles involved Subgroup S, single-muscle correction; subgroup M, multiple-muscle correction. Placebo subgroup S (<italic>n</italic>&#x02009;=&#x02009;16), subgroup M (<italic>n</italic>&#x02009;=&#x02009;15); Ondansetron subgroup S (<italic>n</italic>&#x02009;=&#x02009;12), subgroup M (<italic>n</italic>&#x02009;=&#x02009;14); Ramoseron subgroup S (<italic>n</italic>&#x02009;=&#x02009;17), subgroup M (<italic>n</italic>&#x02009;=&#x02009;15)</p></caption><graphic xlink:href="12871_2016_210_Fig4_HTML" id="MO4"/></fig>
<fig id="Fig5"><label>Fig. 5</label><caption><p>Patient satisfaction regarding the number of EOMs involved. Subgroup S, single-muscle correction; subgroup M, multiple-muscle correction. Placebo subgroup S (<italic>n</italic>&#x02009;=&#x02009;16), subgroup M (<italic>n</italic>&#x02009;=&#x02009;15); Ondansetron subgroup S (<italic>n</italic>&#x02009;=&#x02009;12), subgroup M (<italic>n</italic>&#x02009;=&#x02009;14); Ramoseron subgroup S (<italic>n</italic>&#x02009;=&#x02009;17), subgroup M (<italic>n</italic>&#x02009;=&#x02009;15). VRS, verbal rating scale</p></caption><graphic xlink:href="12871_2016_210_Fig5_HTML" id="MO5"/></fig>
</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par22">PONV is one of the most common causes of unexpected hospitalization in ambulatory strabismus surgery [<xref ref-type="bibr" rid="CR15">15</xref>]. Although the mechanism of PONV after strabismus surgery are not still clearly identified, traction of EOMs, besides from agents used for general anesthesia, is a well-known risk factor for PONV [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par23">In the present study, the incidence of postoperative nausea without prophylaxis was 45.2&#x000a0;% at 2&#x000a0;h and 22.6&#x000a0;% at 24&#x000a0;h after strabismus surgery. This is slightly higher than the previously reported incidence of PONV after strabismus surgery [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. Meanwhile, the incidence of postoperative vomiting without prophylaxis was 0&#x000a0;% in this study unlike those previous studies. However, analysis in these differences is complicated because of differences in study population and anesthetic techniques.</p><p id="Par24">Drugs used to alleviate PONV act on serotonergic, dopaminergic, histaminergic, or cholinergic receptors in the chemoreceptor trigger zone [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Among these, the 5-HT<sub>3</sub> receptor antagonists prevents the emetogenic signal from tranmission to the nucleus tractus solitarii, where most vagal afferents terminate, by regulating serotonin release. 5-HT<sub>3</sub> receptor antagonists exert their effect by inhibiting the binding of serotonin to the 5-HT<sub>3</sub> receptors; they are copious in nucleus tractus solitarii and the chemoreceptor trigger zone which, in turn, project signals to the emetic center located in the brainstem [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par25">Among 5-HT<sub>3</sub> receptor antagonists, ondansetron was the first agent used clinically for PONV. A dose of 4&#x000a0;mg IV at the end of surgery has been reported to be effective for PONV prophylaxis, with a relatively short plasma half-life (3.5&#x02013;4.7&#x000a0;h) and duration of action (~12&#x000a0;h) [<xref ref-type="bibr" rid="CR13">13</xref>]. Tramer et al. [<xref ref-type="bibr" rid="CR7">7</xref>] reported less pronounced antiemetic effect of ondansetron comparing to its anti-vomiting effect. Ondansetron, comparing with placebo, did not improve the patient&#x02019;s satisfaction at any time point although it reduced the incidence of nausea only at 2&#x000a0;h after in our study.</p><p id="Par26">Meanwhile, ramosetron, a newer 5-HT<sub>3</sub> receptor antagonist, has greater affinity for 5-HT<sub>3</sub> receptors and greater potency in consequence, and a longer plasma half life (5.8&#x02009;&#x000b1;&#x02009;1.2&#x000a0;h) and duration of action than other 5-HT<sub>3</sub> receptor antagonists [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Whether ramosetron has a greater antiemetic effect than other 5-HT<sub>3</sub> receptor antagonists is controversial [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Our data suggest that ramosetron has a greater antiemetic effect than ondansetron within 24&#x000a0;h after strabismus surgery. Strabismus surgery is known to be a particularly emetogenic surgical procedure [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Improving patients&#x02019; satisfaction and stronger anti-emetic effect within 24&#x000a0;h after surgery comparing to ondansetron suggest that ramosetron should be administered after strabismus surgery to prevent nausea, because most postoperative nausea occurred within 24&#x000a0;h after surgery in our study population. Meanwhile, the antiemetic effect of ramosetron at 48&#x000a0;h after surgery was similar to that of ondansetron, which corresponds to the report of Halm et al. [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par27">Among various ocular surgeries under general anesthesia, the strabismus surgery is one of the most common surgeries that would result in PONV. Traction of EOMs induces the ocluoemetic reflex and oculocardiac relex, causing bradycardia and hypotension, which are risk factors for PONV [<xref ref-type="bibr" rid="CR11">11</xref>]. Therefore, we hypothesized that more PONV would occur as the number of EOMs involved in strabismus surgery increases, causing more muscle traction. However, this was not supported by our data. The effect of traction of EOMs on PONV after strabismus surgery still remains obscure. Further study is needed to reveal the mechanism of PONV after strabismus surgery.</p><p id="Par28">Pain is a well-known risk factor for PONV, and nausea but not vomiting is the predominant symptom [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. As in the present study, several others have reported that adult patients complain of minimal pain after strabismus surgery with a VAS score&#x02009;&#x0003c;&#x02009;3 [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Moreover, the degree of pain did not differ among any of our groups. Therefore, we suggest that pain has less of an effect on PONV after strabismus surgery.</p><p id="Par29">There are several limitations in our study. First, relatively small number of study population was included. Second, we did not discriminate the patients who had strabismus surgery in both eyes from those who had surgery in only one eye. Although we failed to demonstrate an association between the number of EOMs involved in strabismus surgery and PONV, the binocularity might have been related to PONV. Third, the equivalent doses of ramosetron and ondansetron has not been clearly identified. Various studies have compared the efficacy of 0.3&#x000a0;mg of ramosetron with 4&#x02013;16&#x000a0;mg of ondansetron [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. In a previous animal study, ondansetron did not show a linear dose response curve [<xref ref-type="bibr" rid="CR36">36</xref>], which indicates that it is quite complicated to decide the equivalent doses of ramosetron and ondanseston. Further investigation to verify the equivalent doses of ramosetron and ondansetron is in contemplation.</p></sec><sec id="Sec8"><title>Conclusions</title><p id="Par30">In conclusion, the incidence of postoperative nausea was high until 24&#x000a0;h after strabismus surgery. Therefore, prevention of postoperative nausea during the 24&#x000a0;h after strabismus surgery is crucial. Ramosetron had an antiemetic efficacy greater than that of ondansetron or placebo during the first 24&#x000a0;h after strabismus surgery in adult patients. The number of EOMs involved in strabismus surgery was not associated with the incidence of PONV.</p></sec><sec id="Sec9"><title>Abbreviations</title><p id="Par31">EOM, extraocular muscles; PONV, postoperative nausea and vomiting; TIVA, total intravenous anesthesia; VAS, visual analogue scale; VRS, verbal rating scale</p></sec></body><back><ack><title>Acknowledgements</title><p>We express our gratitude to Professor Yong-gyu Park (Department of statistics, College of Medicine, Seoul St. Mary&#x02019;s Hospital, The Catholic University of Korea) for his support with statistical analysis.</p><sec id="FPar1"><title>Availability of data and materials</title><p id="Par32">The data will not be made available in order to protect the participants identity.</p></sec><sec id="FPar2"><title>Author&#x02019;s contributions</title><p id="Par33">JJ, SHP, HJP and SYS participated in the design of the study. JJ and SYS were responsible for sample collections and logistics. JJ and SYS drafted the manuscript. All authors read and approved the final manuscript.</p></sec><sec id="FPar3"><title>Competing interests</title><p id="Par34">The authors declare that they have no competing interests.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par35">Not applicable.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p id="Par36">This study was approved by Ethical Committee of Seoul St. Mary&#x02019;s Hospital, Catholic University of Korea, ID: KIRB-00332_18-001, and was registered at <ext-link ext-link-type="uri" xlink:href="https://cris.nih.go.kr">cris.nih.go.kr</ext-link>, ID: KCT0000688. Oral and written consent was obtained from all of the patients.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramowitz</surname><given-names>MD</given-names></name><name><surname>Oh</surname><given-names>TH</given-names></name><name><surname>Epstein</surname><given-names>BS</given-names></name><name><surname>Ruttimann</surname><given-names>UE</given-names></name><name><surname>Friendly</surname><given-names>DS</given-names></name></person-group><article-title>The antiemetic effect of droperidol following outpatient strabismus surgery in children</article-title><source>Anesthesiology</source><year>1983</year><volume>59</volume><fpage>579</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1097/00000542-198312000-00021</pub-id><pub-id pub-id-type="pmid">6359968</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowhay</surname><given-names>AR</given-names></name><name><surname>May</surname><given-names>HA</given-names></name><name><surname>Rudnicka</surname><given-names>AR</given-names></name><name><surname>Booker</surname><given-names>PD</given-names></name></person-group><article-title>A randomized controlled trial of the antiemetic effect of three doses of ondansetron after strabismus surgery in children</article-title><source>Paediatr Anaesth</source><year>2001</year><volume>11</volume><fpage>215</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9592.2001.00631.x</pub-id><pub-id pub-id-type="pmid">11240881</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>I</given-names></name><name><surname>Scheifler</surname><given-names>G</given-names></name><name><surname>Wissing</surname><given-names>H</given-names></name></person-group><article-title>Incidence of nausea and vomiting in children after strabismus surgery following desflurane anaesthesia</article-title><source>Paediatr Anaesth</source><year>1999</year><volume>9</volume><fpage>521</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9592.1999.00418.x</pub-id><pub-id pub-id-type="pmid">10597556</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadhasivam</surname><given-names>S</given-names></name><name><surname>Shende</surname><given-names>D</given-names></name><name><surname>Madan</surname><given-names>R</given-names></name></person-group><article-title>Prophylactic ondansetron in prevention of postoperative nausea and vomiting following pediatric strabismus surgery: a dose&#x02013;response study</article-title><source>Anesthesiology</source><year>2000</year><volume>92</volume><fpage>1035</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1097/00000542-200004000-00021</pub-id><pub-id pub-id-type="pmid">10754623</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>TJ</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name><name><surname>Apfel</surname><given-names>CC</given-names></name><name><surname>Chung</surname><given-names>F</given-names></name><name><surname>Davis</surname><given-names>PJ</given-names></name><name><surname>Eubanks</surname><given-names>S</given-names></name><etal/></person-group><article-title>Consensus guidelines for managing postoperative nausea and vomiting</article-title><source>Anesth Analg</source><year>2003</year><volume>97</volume><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1213/01.ANE.0000068580.00245.95</pub-id><pub-id pub-id-type="pmid">12818945</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>TJ</given-names></name></person-group><article-title>Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?</article-title><source>CNS Drugs</source><year>2005</year><volume>19</volume><fpage>225</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.2165/00023210-200519030-00004</pub-id><pub-id pub-id-type="pmid">15740177</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tram&#x000e8;r</surname><given-names>MR</given-names></name><name><surname>Reynolds</surname><given-names>DJ</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>McQuay</surname><given-names>HJ</given-names></name></person-group><article-title>Efficacy, dose&#x02013;response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials</article-title><source>Anesthesiology</source><year>1997</year><volume>87</volume><fpage>1277</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1097/00000542-199712000-00004</pub-id><pub-id pub-id-type="pmid">9416710</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabasseda</surname><given-names>X</given-names></name></person-group><article-title>Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting</article-title><source>Drugs Today (Barc)</source><year>2002</year><volume>38</volume><fpage>75</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1358/dot.2002.38.2.820104</pub-id><pub-id pub-id-type="pmid">12532186</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YS</given-names></name><name><surname>Shim</surname><given-names>JK</given-names></name><name><surname>Yoon</surname><given-names>DH</given-names></name><name><surname>Jeon</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kwak</surname><given-names>YL</given-names></name></person-group><article-title>Effect of ramosetron on patient-controlled analgesia related nausea and vomiting after spine surgery in highly susceptible patients: comparison with ondansetron</article-title><source>Spine (Phila Pa 1976)</source><year>2008</year><volume>33</volume><fpage>E602</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/BRS.0b013e31817c6bde</pub-id><pub-id pub-id-type="pmid">18670328</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahm</surname><given-names>TS</given-names></name><name><surname>Ko</surname><given-names>JS</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Gwak</surname><given-names>MS</given-names></name></person-group><article-title>Comparison of the prophylactic anti-emetic efficacy of ramosetron and ondansetron in patients at high-risk for postoperative nausea and vomiting after total knee replacement</article-title><source>Anaesthesia</source><year>2010</year><volume>65</volume><fpage>500</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2044.2010.06310.x</pub-id><pub-id pub-id-type="pmid">20337618</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>GN</given-names></name></person-group><article-title>Risk factors for postoperative nausea and vomiting</article-title><source>Anaesthesia</source><year>1994</year><volume>49</volume><issue>Suppl</issue><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2044.1994.tb03576.x</pub-id><pub-id pub-id-type="pmid">8129161</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayuhara</surname><given-names>H</given-names></name><name><surname>Takayanagi</surname><given-names>R</given-names></name><name><surname>Okuyama</surname><given-names>K</given-names></name><name><surname>Yoshimoto</surname><given-names>K</given-names></name><name><surname>Ozeki</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><etal/></person-group><article-title>Receptor occupancy theory-based analysis of interindividual differences in antiemetic effect of 5-HT<sub>3</sub> receptor anatagonists</article-title><source>Int J Clin Oncol</source><year>2009</year><volume>14</volume><fpage>518</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s10147-009-0912-5</pub-id><pub-id pub-id-type="pmid">19967488</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>KW</given-names></name><name><surname>White</surname><given-names>PF</given-names></name></person-group><article-title>The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery</article-title><source>Anesth Analg</source><year>1997</year><volume>84</volume><fpage>133</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1213/00000539-199702000-00016</pub-id><pub-id pub-id-type="pmid">8989014</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apfel</surname><given-names>CC</given-names></name><name><surname>Laara</surname><given-names>E</given-names></name><name><surname>Koivuranta</surname><given-names>M</given-names></name><name><surname>Greim</surname><given-names>CA</given-names></name><name><surname>Roewer</surname><given-names>N</given-names></name></person-group><article-title>A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers</article-title><source>Anesthesiology</source><year>1999</year><volume>91</volume><fpage>693</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1097/00000542-199909000-00022</pub-id><pub-id pub-id-type="pmid">10485781</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gayer</surname><given-names>S</given-names></name><name><surname>Lubarsky</surname><given-names>DA</given-names></name></person-group><article-title>Cost-effective Antiemesis</article-title><source>Int Anesthesiol Clin</source><year>2003</year><volume>41</volume><fpage>145</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1097/00004311-200341040-00011</pub-id><pub-id pub-id-type="pmid">14574219</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerman</surname><given-names>J</given-names></name></person-group><article-title>Surgical and patient factors involved in postoperative nausea and vomiting</article-title><source>Br J Anaesth</source><year>1992</year><volume>69</volume><fpage>24S</fpage><lpage>32S</lpage><pub-id pub-id-type="doi">10.1093/bja/69.supplement_1.24S</pub-id><pub-id pub-id-type="pmid">1486011</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watcha</surname><given-names>MF</given-names></name><name><surname>White</surname><given-names>PF</given-names></name></person-group><article-title>Postoperative nausea and vomiting. Its etiology, treatment, and prevention</article-title><source>Anesthesiology</source><year>1992</year><volume>77</volume><fpage>162</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1097/00000542-199207000-00023</pub-id><pub-id pub-id-type="pmid">1609990</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrahim Soltani</surname><given-names>AR</given-names></name><name><surname>Mohammadinasab</surname><given-names>H</given-names></name><name><surname>Goudarzi</surname><given-names>M</given-names></name><name><surname>Arbabi</surname><given-names>S</given-names></name><name><surname>Mohammadinasab</surname><given-names>A</given-names></name><name><surname>Mohammadinasab</surname><given-names>F</given-names></name><etal/></person-group><article-title>Comparing the efficacy of prophylactic p6 acupressure, ondansetron, metoclopramide and placebo in the prevention of vomiting and nausea after strabismus surgery</article-title><source>Acta Med Iran</source><year>2011</year><volume>49</volume><fpage>208</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">21713729</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treschan</surname><given-names>TA</given-names></name><name><surname>Zimmer</surname><given-names>C</given-names></name><name><surname>Nass</surname><given-names>C</given-names></name><name><surname>Stegen</surname><given-names>B</given-names></name><name><surname>Esser</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>J</given-names></name></person-group><article-title>Inspired oxygen fraction of 0.8 does not attenuate postoperative nausea and vomiting after strabismus surgery</article-title><source>Anesthesiology</source><year>2005</year><volume>103</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1097/00000542-200507000-00005</pub-id><pub-id pub-id-type="pmid">15983450</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tram&#x000e8;r</surname><given-names>MR</given-names></name><name><surname>Fuchs-Buder</surname><given-names>T</given-names></name><name><surname>Sansonetti</surname><given-names>A</given-names></name><name><surname>Rifat</surname><given-names>K</given-names></name></person-group><article-title>Low incidence of the oculocardiac reflex and postoperative nausea and vomiting in adults undergoing strabismus surgery</article-title><source>Can J Anaesth</source><year>1997</year><volume>44</volume><fpage>830</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/BF03013159</pub-id><pub-id pub-id-type="pmid">9260010</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klockgether-Radke</surname><given-names>A</given-names></name><name><surname>Feldmann</surname><given-names>M</given-names></name><name><surname>Braun</surname><given-names>U</given-names></name><name><surname>M&#x000fc;hlendyck</surname><given-names>H</given-names></name></person-group><article-title>Droperidol versus metoclopramide. Prevention of emesis following strabismus surgery in children</article-title><source>Anaesthesist</source><year>1992</year><volume>41</volume><fpage>254</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1616115</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlager</surname><given-names>A</given-names></name><name><surname>Mitterschiffthaler</surname><given-names>G</given-names></name><name><surname>P&#x000fc;hringer</surname><given-names>F</given-names></name></person-group><article-title>Rectally administered dimenhydrinate reduces postoperative vomiting in children after strabismus surgery</article-title><source>Br J Anaesth</source><year>2000</year><volume>84</volume><fpage>405</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.bja.a013450</pub-id><pub-id pub-id-type="pmid">10793607</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broomhead</surname><given-names>CJ</given-names></name></person-group><article-title>Physiology of postoperative nausea and vomiting</article-title><source>Br J Hosp Med</source><year>1995</year><volume>53</volume><fpage>327</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">7788070</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovac</surname><given-names>AL</given-names></name></person-group><article-title>Prevention and treatment of postoperative nausea and vomiting</article-title><source>Drugs</source><year>2000</year><volume>59</volume><fpage>213</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.2165/00003495-200059020-00005</pub-id><pub-id pub-id-type="pmid">10730546</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>MM</given-names></name><name><surname>Siddiqui</surname><given-names>OA</given-names></name><name><surname>Haleem</surname><given-names>S</given-names></name><name><surname>Varshney</surname><given-names>R</given-names></name><name><surname>Akhtar</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>FA</given-names></name></person-group><article-title>Comparison of ramosetron and ondansetron for control of post-operative nausea and vomiting following laparoscopic cholecystectomy</article-title><source>Indian J Med Sci</source><year>2010</year><volume>64</volume><fpage>272</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.4103/0019-5359.99606</pub-id><pub-id pub-id-type="pmid">22885319</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>EG</given-names></name></person-group><article-title>Comparison of ramosetron&#x02019;s and ondansetron&#x02019;s preventive anti-emetic effects in highly susceptible patients undergoing abdominal hysterectomy</article-title><source>Korean J Anesthesiol</source><year>2011</year><volume>61</volume><fpage>488</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.4097/kjae.2011.61.6.488</pub-id><pub-id pub-id-type="pmid">22220226</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>J</given-names></name><name><surname>So</surname><given-names>YM</given-names></name><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Do</surname><given-names>SH</given-names></name></person-group><article-title>Ramosetron versus ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy</article-title><source>Surg Endosc</source><year>2010</year><volume>24</volume><fpage>812</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1007/s00464-009-0670-5</pub-id><pub-id pub-id-type="pmid">19707823</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Mandal</surname><given-names>RD</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><etal/></person-group><article-title>PONV in Ambulatory surgery: a comparison between Ramosetron and Ondansetron: a prospective, double-blinded, and randomized controlled study</article-title><source>Saudi J Anaesth</source><year>2014</year><volume>8</volume><fpage>25</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24665236</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roh</surname><given-names>GU</given-names></name><name><surname>Yang</surname><given-names>SY</given-names></name><name><surname>Shim</surname><given-names>JK</given-names></name><name><surname>Kwak</surname><given-names>YL</given-names></name></person-group><article-title>Efficacy of palonosetron versus ramosetron on preventing opioid-based analgesia-related nausea and vomiting after lumbar spinal surgery: a prospective, randomized, and double-blind trial</article-title><source>Spine (Phila Pa 1976)</source><year>2014</year><volume>39</volume><fpage>E543</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/BRS.0000000000000236</pub-id><pub-id pub-id-type="pmid">24480956</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Lim</surname><given-names>YJ</given-names></name><name><surname>Hong</surname><given-names>DM</given-names></name><name><surname>Park</surname><given-names>HP</given-names></name><name><surname>Han</surname><given-names>JI</given-names></name><etal/></person-group><article-title>A prospective, randomized, double-blind, and multicenter trial of prophylactic effects of ramosetronon postoperative nausea and vomiting (PONV) after craniotomy: comparison with ondansetron</article-title><source>BMC Anesthesiol</source><year>2014</year><volume>14</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/1471-2253-14-63</pub-id><pub-id pub-id-type="pmid">25104916</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>AY</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Hwang</surname><given-names>JW</given-names></name><name><surname>Do</surname><given-names>SH</given-names></name><name><surname>Jeon</surname><given-names>YT</given-names></name></person-group><article-title>Incidence of postoperative nausea and vomiting after paediatric strabismus surgery with sevoflurane or remifentanil-sevoflurane</article-title><source>Br J Anaesth</source><year>2010</year><volume>104</volume><fpage>756</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1093/bja/aeq091</pub-id><pub-id pub-id-type="pmid">20418533</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagtekin</surname><given-names>O</given-names></name><name><surname>Wiese</surname><given-names>P</given-names></name><name><surname>Wolter</surname><given-names>K</given-names></name><name><surname>Hermann</surname><given-names>MM</given-names></name><name><surname>Pietruck</surname><given-names>C</given-names></name><name><surname>Kampe</surname><given-names>S</given-names></name></person-group><article-title>Haloperidol versus haloperidol plus ondansetron for the prophylaxis of postoperative nausea and vomiting after ophthalmologic surgery</article-title><source>Pharmacology</source><year>2009</year><volume>83</volume><fpage>205</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1159/000196812</pub-id><pub-id pub-id-type="pmid">19174617</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachko</surname><given-names>L</given-names></name><name><surname>Katz</surname><given-names>J</given-names></name><name><surname>Axer-Siegel</surname><given-names>R</given-names></name><name><surname>Friling</surname><given-names>R</given-names></name><name><surname>Goldenberg-Cohen</surname><given-names>N</given-names></name><name><surname>Simhi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Sub-Tenon&#x02019;s ropivacaine block for pain relief after primary strabismus surgery</article-title><source>Curr Eye Res</source><year>2010</year><volume>35</volume><fpage>529</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.3109/02713681003658289</pub-id><pub-id pub-id-type="pmid">20465448</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Ai</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: a prospective randomized controlled study</article-title><source>Chemotherapy</source><year>2007</year><volume>53</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1159/000098418</pub-id><pub-id pub-id-type="pmid">17202811</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Baek</surname><given-names>YH</given-names></name><name><surname>Ok</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name></person-group><article-title>Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynecological surgery</article-title><source>Br J Anaesth</source><year>2009</year><volume>103</volume><fpage>549</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1093/bja/aep209</pub-id><pub-id pub-id-type="pmid">19700442</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>PL</given-names></name><name><surname>Bhandari</surname><given-names>P</given-names></name><name><surname>Davey</surname><given-names>PT</given-names></name><name><surname>Bingham</surname><given-names>S</given-names></name><name><surname>Marr</surname><given-names>HE</given-names></name><name><surname>Blower</surname><given-names>PR</given-names></name></person-group><article-title>Are all 5-HT3 receptor antagonists the same?</article-title><source>Eur J Cancer</source><year>1992</year><volume>28A</volume><issue>Suppl</issue><fpage>S2</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/0959-8049(92)90628-F</pub-id><pub-id pub-id-type="pmid">1320915</pub-id></element-citation></ref></ref-list></back></article>